Business Context and Reporting Period
Company: Hemispherx Biopharma, Inc. (Note: Input metadata referenced "AIM Immunotech Inc." but the filing text identifies Hemispherx Biopharma, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: December 22, 2010
Subject: Non-reliance on previously issued financial statements due to a change in accounting treatment regarding warrant liabilities.
Key Financial Metrics and Impact
The filing details a restatement of financial statements for the year ended December 31, 2009, and the first three quarters of 2010. The adjustments are non-cash and relate to the fair value of warrant liabilities.
- Initial Liability (May 2009): $15,233,000 (to be recorded as a decrease in Additional Paid-In Capital and increase in Liabilities).
- 2009 Net Loss Adjustment: The restatement is expected to reduce the reported 2009 Net Loss from approximately $13,438,000 to $8,883,000.
- 2009 Net Non-Cash Gain: Approximately $4,555,000 (derived from a $4,256,000 loss on warrant exercises offset by an $8,811,000 gain from fair value adjustments).
- 2010 Q1-Q3 Non-Cash Gain: Approximately $815,000.
- Warrant Liability Balances (Restated Estimates):
- December 31, 2009: $3,162,000
- March 31, 2010: $4,223,000
- June 30, 2010: $2,096,000
- September 30, 2010: $2,346,000
Material Changes Versus Prior Period
The primary material change is the reversal of the company's previous accounting decision to value the warrant liability at zero. Previously, the company deemed the probability of a "Fundamental Transaction" (triggering cash settlement) to be remote. Following an SEC comment letter and review by their independent auditors (McGladrey & Pullen, LLP), the company determined that the liability must be recorded without regard to the probability of cash settlement. Consequently, all financial statements from the second quarter of 2009 through the third quarter of 2010 are no longer reliable.
Outlook, Risks, and Management Commentary
- Management Commentary: The CFO and CEO reviewed the valuation process and concluded that while a restatement is necessary, the original use of a "remoteness factor" did not constitute a material weakness in internal controls, as they relied on independent appraisers and current accounting literature at the time.
- Operational Impact: Management states that these non-cash adjustments will not affect revenues, operating expenses, liquidity, or cash flows from operations, except in the highly unlikely event the company is taken private.
- Risks/Contingencies: The filing notes that the disclosed financial impacts are estimates and are subject to change upon finalization of the restatement.
Investor Verification Checklist
- Verify the final restated financial statements for the periods ending June 30, 2009, September 30, 2009, December 31, 2009, March 31, 2010, June 30, 2010, and September 30, 2010.
- Confirm the exact final valuation of the warrant liability and the corresponding adjustment to Additional Paid-In Capital.
- Review the company's updated internal control disclosures to ensure no material weakness is formally identified in future filings.
- Monitor for any actual cash settlement events related to the warrants, though management deems this highly unlikely.